Octava

Octava is a Singapore-based investment firm whose publicly visible positioning suggests a family-office or private capital orientation rather than a traditional venture fund. The source data carries no disclosed healthcare thesis, AI focus, stage preference or check size, but the Singapore base implies APAC market access, sovereign-adjacent network effects, and patient-capital tendencies typical of regional family offices. For healthcare founders, this profile is most relevant when expanding into Southeast Asia, building regulatory or distribution partnerships in the region, or seeking long-duration capital from an LP-style investor. Plausible check sizes for a firm of this profile span a wide range, from a few hundred thousand for venture-style positions to several million for direct private investments, depending on entry deal structure and the firm’s appetite for the specific opportunity. Octava is most likely a fit for later-stage, commercial-stage healthcare businesses with proven unit economics seeking strategic Asia exposure, rather than for early-stage US or European startups looking for hands-on operational support. Pre-revenue biotech and any company expecting deep clinical pattern-matching from the investor are likely poor fits. The realistic entry path is a warm introduction via Asia-based LPs, regional bankers or family-office network connectors, or a direct LinkedIn approach to investment principals; cold outbound from the West with no Asia angle is unlikely to land. Founders should clarify fund versus balance-sheet structure, expected hold period, geographic preferences and any required regional partnership or commercial commitment in early conversations before investing diligence time.